NextCure (NASDAQ:NXTC) Cut to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of NextCure (NASDAQ:NXTC) from a hold rating to a sell rating in a report issued on Wednesday morning, Zacks.com reports.

According to Zacks, “NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company’s product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland. “

A number of other equities research analysts have also recently weighed in on NXTC. Bank of America assumed coverage on NextCure in a report on Tuesday, July 9th. They set a buy rating and a $25.00 price target on the stock. Piper Jaffray Companies assumed coverage on NextCure in a report on Monday, June 3rd. They set an overweight rating and a $26.00 target price on the stock. Finally, Morgan Stanley boosted their target price on NextCure from $25.00 to $33.00 and gave the stock an overweight rating in a report on Tuesday, August 13th.

NXTC opened at $30.13 on Wednesday. The company’s 50 day simple moving average is $21.24. The company has a current ratio of 17.05, a quick ratio of 17.05 and a debt-to-equity ratio of 0.02. NextCure has a twelve month low of $13.86 and a twelve month high of $30.97.

NextCure (NASDAQ:NXTC) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.15). The firm had revenue of $1.40 million during the quarter, compared to the consensus estimate of $1.50 million. As a group, analysts anticipate that NextCure will post -1.89 earnings per share for the current year.

A number of large investors have recently made changes to their positions in NXTC. Orbimed Advisors LLC acquired a new position in NextCure during the 2nd quarter worth $40,611,000. Victory Capital Management Inc. acquired a new position in NextCure during the 2nd quarter worth $48,000. Citadel Advisors LLC acquired a new position in NextCure during the 2nd quarter worth $16,385,000. Hillhouse Capital Advisors LTD. acquired a new position in NextCure during the 2nd quarter worth $1,124,000. Finally, Hillhouse Capital Management LTD. acquired a new position in NextCure during the 2nd quarter worth $14,659,000. 15.32% of the stock is currently owned by hedge funds and other institutional investors.

About NextCure

There is no company description available for NextCure Inc

Recommended Story: The components of the Stochastic Momentum Index

Get a free copy of the Zacks research report on NextCure (NXTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.